Education
About Us
Working with TipRanks
Follow Us
Delcath Systems (DCTH)
NASDAQ:DCTH
DCTH Stock Chart & Stats
Day’s Range― - ―
52-Week Range$7.54 - $18.23
Previous CloseN/A
Volume96.76K
Average Volume (3M)833.65K
Market Cap
$366.25M
Enterprise Value$467.56M
Total Cash (Recent Filing)$81.00M
Total Debt (Recent Filing)$993.00K
Price to Earnings (P/E)227.7
Beta1.16
Next Earnings
Nov 11, 2025EPS Estimate
-0.04Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)0.07
Shares Outstanding34,981,255
10 Day Avg. Volume1,119,862
30 Day Avg. Volume833,652
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
P/FCF RatioN/A
Enterprise Value/Market Cap1.28
Enterprise Value/Revenue6.82
Enterprise Value/Gross Profit7.75
Enterprise Value/Ebitda35.13
Forecast
1Y Price Target
$23.00Price Target Upside122.01% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering6
Bulls Say, Bears Say
Bulls Say
Expansion And AdoptionHEPZATO’s participation in the Medicaid National Drug Rebate Agreement (NDRA) program is expected to increase access and thus overall treatment volumes.
Market OpportunityDelcath estimates a combined $1.0B market opportunity for Hepzato in liver metastases due to colorectal and breast cancer, an attractive long-term growth opportunity.
Revenue GrowthHepzato and Chemosat revenue beat consensus, signaling continued growth.
Bears Say
Pricing ImpactDelcath plans to participate in 340b program and introduce a ~23.1% discount on Hepzato sold to all 340b hospitals.
Revenue GuidanceManagement modestly lowered 2025 revenue guidance to $93M-$96M, from prior $94M-$98M.
Delcath Systems News
DCTH FAQ
What was Delcath Systems’s price range in the past 12 months?
Delcath Systems lowest stock price was $7.54 and its highest was $18.23 in the past 12 months.
What is Delcath Systems’s market cap?
Delcath Systems’s market cap is $366.25M.
When is Delcath Systems’s upcoming earnings report date?
Delcath Systems’s upcoming earnings report date is Nov 11, 2025 which is in 86 days.
How were Delcath Systems’s earnings last quarter?
Delcath Systems released its earnings results on Aug 06, 2025. The company reported $0.07 earnings per share for the quarter, beating the consensus estimate of $0.027 by $0.043.
Is Delcath Systems overvalued?
According to Wall Street analysts Delcath Systems’s price is currently Undervalued.
Does Delcath Systems pay dividends?
Delcath Systems does not currently pay dividends.
What is Delcath Systems’s EPS estimate?
Delcath Systems’s EPS estimate is -0.04.
How many shares outstanding does Delcath Systems have?
Delcath Systems has 34,981,255 shares outstanding.
What happened to Delcath Systems’s price movement after its last earnings report?
Delcath Systems reported an EPS of $0.07 in its last earnings report, beating expectations of $0.027. Following the earnings report the stock price went up 1.141%.
Which hedge fund is a major shareholder of Delcath Systems?
Currently, no hedge funds are holding shares in DCTH
Delcath Systems Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$23.00 (122.01% Upside)
$23.00 (122.01% Upside)
Blogger Sentiment
Bullish
DCTH Sentiment 100%
Sector Average 70%
Sector Average 70%
Hedge Fund Trend
Decreased
By 983.1K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Positive
Last 7 Days ▲ 1.8%
Last 30 Days ▲ 9.9%
Last 30 Days ▲ 9.9%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
38.31%
12-Months-Change
Fundamentals
Return on Equity
4.09%
Trailing 12-Months
Asset Growth
244.63%
Trailing 12-Months
Company Description
Delcath Systems
Delcath Systems, Inc. is a biopharmaceutical company focused on developing and commercializing innovative therapies for the treatment of cancer. The company primarily operates in the oncology sector, specializing in its proprietary Chemosaturation Technology System (CTS), which is designed to deliver high-dose chemotherapy directly to tumors while minimizing systemic exposure. Delcath's core product offerings include the CTS for the treatment of liver cancers, particularly in patients with metastatic melanoma and other tumors that have spread to the liver.
DCTH Earnings Call
Q2 2025
0:00 / 0:00
Earnings Call Sentiment|Neutral
The earnings call reflected a balanced outlook. While Delcath Systems showcased strong revenue growth, positive cash flow, and strategic expansion of treating sites, challenges such as slower site activations and increased expenses were noted. Adjustments in financial guidance due to the 340B program also posed potential challenges. However, the company's proactive initiatives in R&D and pipeline expansion position it well for future growth.View all DCTH earnings summariesDCTH Stock 12 Month Forecast
Average Price Target
$23.00
▲(122.01% Upside)
Technical Analysis
SurModics
―
ClearPoint Neuro
―
Senseonics Holdings
―
Nano-X Imaging
―
Treace Medical Concepts
―
Ownership Overview
31.14% Insiders
5.02% Mutual Funds
23.16% Other Institutional Investors
30.67% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---